Table 2 Efficacy of contact precautions on ICU ESBL-E dissemination in a non-outbreak situation
Year | Authors | Design | N | Outcome | Brief results |
|---|---|---|---|---|---|
2018 | Jalalzaï et al. [30] | Unicentric, retrospective, uncontrolled before-and-after study | 524 SCP 545 non-SCP with SP | ICU-acquired ESBL-E infections ICU deaths | No independent impact on ESBL-E infections of cessation of admission screening (adjusted OR 1.16, 95% CI 0.38–3.50, p = 0.79) nor on in-ICU death (SHR 1.22, 95% CI 0.93–1.59, p = 0.15) |
2017 | Kardas-Stoma et al. [32] | Cost-effectiveness analysis | NA | ICU-acquired ESBL-E fecal carriage ICU-acquired ESBL-E infections | Universal screening and contact precautions for ESBL-E fecal carriers vs base care, per 100 admissions 12 vs 15 ICU-acquired ESBL-E fecal carriage 4 vs 5 ICU-acquired ESBL-E infections |
2017 | Renaudin et al. [31] | Prospective non-inferiority before-and-after study | 1547 CP 1577 SP | ICU-acquired ESBL-E fecal carriage | Incidence densities respectively during CP and SP: 2.7 (95% CI 1.78–3.62), 2.06 (95% CI 1.27–2.86) per 1000 patient-days; p 0.004 for non-inferiority |
2014 | Derde et al. [29] | Prospective, randomized, interrupted, time series study | 8501 | ICU-acquired ESBL-E fecal carriage with and without CP | Incidence rate ratio: 0.994 (0.968–1.021; p 0.66) comparing with and without CP |